CLAIMS

1. Use of a solid pharmaceutical composition in the manufacture of a medicament for treating pain in a human being in need thereof, wherein the solid pharmaceutical composition comprises a bicarbonate, a meloxicam or pharmaceutically acceptable salt thereof, and a sulfobutyl ether β-cyclodextrin (SBEβCD) or pharmaceutically acceptable salt thereof, wherein the meloxicam or pharmaceutically acceptable salt thereof and the SBEβCD or pharmaceutically acceptable salt thereof have a molar ratio of 0.8 to 1.2, wherein the bicarbonate provides improved dissolution of meloxicam or pharmaceutically acceptable salt thereof in gastric fluid as compared with a first reference pharmaceutical composition that: 1) contains the same amount of the meloxicam or pharmaceutically acceptable salt thereof; 2) does not contain a bicarbonate; and 3) does not contain a carbonate, wherein the medicament is formulated for oral administration to the human being, wherein the solid pharmaceutical composition comprises between 1 mg to 50 mg of meloxicam or a pharmaceutically acceptable salt thereof, and wherein the solid pharmaceutical composition contains 400 mg to 1000 mg of the bicarbonate.

2. Use of a solid pharmaceutical composition in the manufacture of a medicament for treating pain in a human being in need thereof, wherein the solid pharmaceutical composition comprises a bicarbonate, a meloxicam or pharmaceutically acceptable salt thereof, and a sulfobutyl ether β-cyclodextrin (SBEβCD) or pharmaceutically acceptable salt thereof, wherein the meloxicam or pharmaceutically acceptable salt thereof and the SBEβCD or pharmaceutically acceptable salt thereof have a molar ratio of 0.8 to 1.2, wherein the bicarbonate provides improved dissolution of meloxicam or pharmaceutically acceptable salt thereof in gastric fluid as compared with a second reference pharmaceutical composition that: 1) contains the same amount of the meloxicam or pharmaceutically acceptable salt thereof; 2) contains an amount of a carbonate that achieves about the same pH as the bicarbonate; and 3) does not contain a bicarbonate, wherein the medicament is formulated for oral administration to the human being, wherein the solid pharmaceutical composition comprises between 1 mg to 50 mg of meloxicam or a pharmaceutically acceptable salt thereof, and

wherein the solid pharmaceutical composition contains 400 mg to 1000 mg of the bicarbonate.

3. Use according to claim 1 or 2, wherein the solid pharmaceutical composition comprises a pharmaceutically acceptable excipient.

4. Use according to any one of the preceding claims, wherein the solid pharmaceutical composition further comprises an acid inhibitor.

5. Use according to claim 4, wherein the acid inhibitor is esomeprazole or a pharmaceutically acceptable salt thereof.

6. Use according to any one of the preceding claims, wherein the solid pharmaceutical composition is in a tablet form.

7. Use according to any one of the preceding claims, wherein the solid pharmaceutical composition comprises about 15 mg of meloxicam or pharmaceutically acceptable salt thereof.

8. Use according to any one of claims 1 to 6, wherein the solid pharmaceutical composition comprises about 20 mg of meloxicam or pharmaceutically acceptable salt thereof.

9. Use according to any one of the preceding claims, wherein the bicarbonate is sodium bicarbonate or potassium bicarbonate.

10. Use according to any one of the preceding claims, wherein the solid pharmaceutical composition comprises 500 mg of sodium bicarbonate.

11. Use according to claim 2, wherein the carbonate in the second reference pharmaceutical composition is potassium carbonate.

12. Use according to any one of claims 5 to 11, wherein between 30 mg to 50 mg of esomeprazole or a pharmaceutically acceptable salt thereof is present in the solid pharmaceutical composition.

13. Use according to any one of the preceding claims, wherein, 120 minutes after oral administration of the solid pharmaceutical composition, the dissolution of meloxicam or pharmaceutically acceptable salt thereof is at least 3 times that of the first or the second reference pharmaceutical composition.

14. Use according to any one of claims 3 to 12, wherein, 120 minutes after oral administration of the solid pharmaceutical composition, the dissolution of meloxicam or pharmaceutically acceptable salt thereof is at least 5 times that of the first or the second reference pharmaceutical composition.

15. Use according to any one of the preceding claims, wherein, 15 minutes after oral administration of the solid pharmaceutical composition, the dissolution of meloxicam or pharmaceutically acceptable salt thereof is at least 10% more than that of the first or the second reference pharmaceutical composition.

16. Use according to any one of claims 3 to 12, wherein, 15 minutes after oral administration of the solid pharmaceutical composition, the dissolution of meloxicam or pharmaceutically acceptable salt thereof is at least 2 times that of the first or the second reference pharmaceutical composition.

17. Use according to any one of the preceding claims, wherein the pain is inflammatory pain.

18. Use according to any one of claims 1 to 16, wherein the solid pharmaceutical composition is to be orally administered to the human being to treat pain associated with osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis.

19. Use according to any one of the preceding claims, wherein the pain is migraine pain.

20. Use of a solid pharmaceutical composition in the manufacture of a medicament for treating pain in a human being in need thereof, wherein the solid pharmaceutical composition comprises sodium bicarbonate, 20 mg of meloxicam or a pharmaceutically acceptable salt thereof, and 113.6 mg of sulfobutyl ether β-cyclodextrin (SBEβCD) or a pharmaceutically acceptable salt thereof, wherein the bicarbonate provides improved dissolution of meloxicam or pharmaceutically acceptable salt thereof in gastric fluid as compared with a first reference pharmaceutical composition that: 1) contains the same amount of the meloxicam or pharmaceutically acceptable salt thereof; 2) does not contain a bicarbonate; and 3) does not contain a carbonate, wherein the medicament is formulated for oral administration to the human being, and wherein the solid pharmaceutical composition contains 400 mg to 1000 mg of the bicarbonate.